[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nonalcoholic-fatty-liver\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nonalcoholic-fatty-liver":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,58,83,111,142,165],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100556317","phase-4-effect-of-a-gnrh-analog-on-hepatic-steatosis-100556317",false,"NCT06523530","Effect of a GnRH Analog on Hepatic Steatosis","Effect of the Pharmacological Cessation of Menstruation With a GnRH Analog on Hepatic Steatosis in Women With Endometriosis","EndomMASLD","Inclusion Criteria:\n\n* women of reproductive age\n* diagnosis of endometriosis. The disease is suspected by patient's individual history (chronic pelvic pain, dyspareunia or\u002Fand dysmenorrhea) and the ultrasonographic imaging (chocolate cysts). The diagnosis is confirmed histologically, after laparoscopic surgical treatment and biopsy sampling, which will be interpreted by an independent blinded pathologist.\n* use of contraceptives, which is the first line treatment, is contraindicated or the patient does not consent to receive contraceptives, due to personal preferences.\n* written informed consent to participate to the study\n\nExclusion Criteria:\n\n* mean ethanol consumption \\>10 g\u002Fday\n* history of other chronic liver disease (e.g., viral hepatitis, autoimmune hepatitis, primary sclerosing cholangitis, primary biliary cholangitis and overlap syndromes, drug-induced liver injury, hemochromatosis, Wilson's disease, α1-antitrypsin deficiency)\n* liver cirrhosis\n* any malignancy\n* chronic kidney disease\n* uncontrolled hypothyroidism or hyperthyroidism\n* severe sexual hormone disorders (congenital adrenaline hyperplasia, Down syndrome, Turner syndrome).\n* use of the following medications within a 12-month period before baseline, which are associated with drug-induced liver injury (DILI): interferon, tamoxifen, amiodarone, aloperidin, glucocorticoids, hormone replacement therapy, contraceptives, anabolic steroids, any medication against tuberculosis, epilepsy or viruses, methotrexate, parenteral nutrition\n* use of the following medications within a 12-month period before baseline, which are probably associated with improvement in hepatic steatosis: vitamin E, pioglitazone, insulin, glucagon-like peptide-1 receptor agonists (GLP-1RAs), sodium- glucose co-transporter-2 inhibitors (SGLT-2i), orlistat, ursodeoxycholic acid\n* use of any GnRH agonist or antagonist within a 12-month period before baseline","FEMALE","18 Years","45 Years",{"count":21,"type":22},62,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","Menopause increases the risk of metabolic dysfunction-associated steatotic liver disease (MASLD), possibly owing to the abrupt lack of estrogen. Gonadotropin-releasing hormone (GnRH) treatment in endometriosis is regarded as a model of pharmaceutical menopause. Thus, the effect of goserelin acetate, a GnRH analog that results in transient menopause, on hepatic steatosis and fibrosis will be evaluated in this study.",[28,29,30],"Metabolic Dysfunction-Associated Steatotic Liver Disease","Nonalcoholic Fatty Liver","Endometriosis",[32,33,34,35,36,37,38,39,40,41,42,43,44],"endometriosis","goserelin acetate","hepatic fibrosis","MASLD","MASH","metabolic dysfunction-associated steatotic liver disease","metabolic dysfunction-associated steatohepatitis","NAFLD","NASH","nonalcoholic fatty liver disease","nonalcoholic steatohepatitis","treatment","menopause","RECRUITING","2026-02-01",{"date":48,"type":49},"2026-02-03","ACTUAL",{"date":51,"type":49},"2024-11-26",{"date":53,"type":22},"2027-10",{"name":55,"class":56},"Aristotle University Of Thessaloniki","OTHER",2,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":64,"minAge":65,"maxAge":19,"enrollmentInfo":66,"targetDuration":4,"studyType":23,"phases":68,"briefSummary":70,"conditions":71,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100608390","effect-of-adding-tens-to-mediterranean-diet-on-appetite-and-liver-enzymes-in-nonalcoholic-fatty-liver-patients-100608390","NCT07200934","Effect of Adding TENS to Mediterranean Diet on Appetite and Liver Enzymes in Nonalcoholic Fatty Liver Patients","Inclusion Criteria:\n\n* The age will range from 35-45 years old.\n* BMI (Body Mass Index 30-34.9 kg\u002Fm2.)\n* With fatty liver infiltration confirmed by abdominal ultrasound\n* Elevated of liver enzymes as a primary marker\n* All patients are psychologically stable.\n\nExclusion Criteria:\n\n* History of cardiovascular or respiratory disease.\n* If any known endocrine diseases e.g. Hypothyroidism (which elevates liver enzymes and effects on appetite)\n* Any acute or chronic illness causing elevated liver enzymes other than fatty liver e.g. Hepatitis b, Hepatitis c\n* Any neurological illness or impairment can effect on sensation\n* Patients associated with infections, mental or malignant conditions.\n* Patients who have undergone any gastric surgery e.g. Bariatric surgery\n* Taking dietary supplement for weight reduction.\n* Patients who participating in any other exercise program.","MALE","35 Years",{"count":67,"type":22},50,[69],"NA","This study aims to identify the effect of adding TENS to the Mediterranean diet on appetite and liver enzymes in Nonalcoholic fatty liver patients.",[29],"NOT_YET_RECRUITING","2025-09-23",{"date":75,"type":49},"2025-10-01",{"date":77,"type":22},"2025-09-30",{"date":79,"type":22},"2026-01-14",{"name":81,"class":56},"Cairo University",1,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":91,"sex":92,"minAge":18,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":96,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":82},"100541892","harnessing-macrophage-lysosomal-lipid-metabolism-in-obesity-100541892","NCT06335771","Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity","Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity-Associated Diseases","ATM","Inclusion Criteria :\n\n* age: ≥18 but ≤70 years\n* not pregnant or breastfeeding\n* weight stable and sedentary before enrollment\n* no use tobacco products, excessive amounts of alcohol, or dietary supplements, or medications known to or suspected to affect glucose and lipid metabolism (aside from certain medications used to treat diabetes in the metabolically abnormal obesity \\[MAO\\]-Type 2 Diabetes group)\n* no evidence of significant organ system dysfunction or disease (e.g. chronic severe kidney disease, cancer)\n* participants must fulfil all of the following group-specific inclusion criteria below:\n\nLean group:\n\n* Body mass index (BMI) ≥18.5 but \\\u003C25.0 kg\u002Fm2\n* Intrahepatic triglyceride (IHTG) content \\\u003C5%\n* fasting blood glucose concentration: \\\u003C100 mg\u002Fdl\n* blood glucose concentration 2 h after a 75 g oral glucose challenge: \\\u003C140 mg\u002Fdl\n* Hemoglobin A1C (HbA1c) \\\u003C5.7 %\n\nMetabolically normal obesity (MNO) group:\n\n* BMI ≥30.0 but \\\u003C45.0 kg\u002Fm2\n* IHTG content \\\u003C5%\n* fasting blood glucose concentration: \\\u003C100 mg\u002Fdl\n* blood glucose concentration 2 h after a 75 g oral glucose challenge: \\\u003C140 mg\u002Fdl\n* HbA1c \\\u003C5.7 %\n\nMetabolically abnormal obesity (MAO)-insulin resistance and non-alcoholic fatty liver disease (NAFLD) group:\n\n* BMI ≥30.0 but \\\u003C45.0 kg\u002Fm2\n* IHTG content \\>7.5%\n* fasting blood glucose concentration: ≥100 but \\\u003C126 mg\u002Fdl\n* blood glucose concentration 2 h after a 75 g oral glucose challenge: ≥140 but \\\u003C200 mg\u002Fdl\n* HbA1c: ≥5.7 but \\\u003C6.4 %\n\nMAO-type 2 diabetes group:\n\n* BMI ≥30.0 but \\\u003C45.0 kg\u002Fm2\n* clinical diagnosis of type 2 diabetes or fasting blood glucose concentration \\>126 mg\u002Fdl or blood glucose concentration 2 h after a 75 g oral glucose challenge\\>200 mg\u002Fdl or HbA1c \\>6.4 % without medication if not diagnosed and medically treated for diabetes\n\nExclusion Criteria:\n\n\\- Individuals that do not meet all inclusion Criterion",true,"ALL","70 Years",{"count":95,"type":22},60,[69],"The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity. The investigators will assess the differences in ATM lipid metabolism in people with metabolically abnormal obesity and lean individuals.\n\nBoth groups will have:\n\n* screening visit\n* imaging (body composition testing - dual-energy x-ray absorptiometry (DEXA) scans, magnetic resonance imaging \\[MRI\\] and magnetic resonance spectroscopy \\[MRS\\] scans)\n* Overnight visit with intravenous infusion (IV), muscle, and fat tissue biopsies Participants with obesity will complete meetings with study team members for a weight loss intervention to achieve a 10% body weight loss.",[99,29,100,101],"Obesity","Diabetes Type 2","Healthy","2025-07-16",{"date":104,"type":49},"2025-07-18",{"date":106,"type":49},"2024-08-01",{"date":108,"type":22},"2028-03",{"name":110,"class":56},"Bettina Mittendorfer",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":91,"sex":92,"minAge":65,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":23,"phases":120,"briefSummary":121,"conditions":122,"keywords":128,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":82},"100451992","longitudinal-multi-omic-profiles-to-reveal-mechanisms-of-obesity-mediated-insulin-resistance-100451992","NCT05165706","Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance","Inclusion Criteria:\n\n* Age 35-65\n* BMI 25-35 kg\u002Fm2\n* Stable body weight\n* Nondiabetic\n\nExclusion Criteria:\n\nPatients with;\n\n* diabetes\n* major organ disease\n* history of liposuction or bariatric surgery\n* active eating or psychiatric disorder\n* pregnancy or lactation, heavy alcohol use\n* recent change in weight (over the past 12 weeks)\n* use of weight loss medication, statins, or oral steroids\n\nClinical screening exclusions;\n\n* hematocrit \\\u003C 33%\n* fasting glucose \\>\u002F= 126 mg\u002FdL\n* blood pressure \\>160\u002F100 mmHg","65 Years",{"count":119,"type":22},110,[69],"This 12-week controlled diet and weight intervention study seeks to define the molecular pathways that link excess body weight to the development of insulin resistance (IR). Blood, adipose and stool are sampled at three timepoints; baseline, peak weight (4 weeks) and post weight loss to monitor changes in cellular processes. Additionally, direct insulin sensitivity testing, and radiological measurement of visceral fat and intrahepatic fat content is measured at three timepoints to correlate clinical indices with cellular changes.",[123,124,125,99,126,29,127],"Diabetes Mellitus, Type 2","PreDiabetes","Insulin Resistance","Nonalcoholic Steatohepatitis","Diet Modification",[129,130,131,132],"Metabolomics","Low Fat Diet","Low Carbohydrate Diet","Microbiome","2024-12-02",{"date":135,"type":49},"2024-12-04",{"date":137,"type":49},"2019-01-31",{"date":139,"type":22},"2026-12-30",{"name":141,"class":56},"Stanford University",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":91,"sex":92,"minAge":149,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":23,"phases":153,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":82},"100472307","metabolic-pathology-of-pediatric-nafld-100472307","NCT05430178","Metabolic Pathology of Pediatric NAFLD","Understanding the Metabolic Pathology of Pediatric Obesity and NAFLD","Inclusion Criteria:\n\n* Age: All participants must be 10.0 to 20.9 years old at the time of enrollment.\n* Sex: Male and Female participants are eligible.\n* Race\u002FEthnicity: Participants of all racial\u002Fethnic identities will be recruited.\n* Body mass index (BMI): Participants must be either in the normal weight (NW control group) or obese \\[Ob control, nonalcoholic fatty liver disease (NALFD) groups\\] range for BMI percentile. BMI percentile will be calculated from age- and sex-specific growth charts for children.\n* NAFLD status: The NAFLD group participants will be eligible if they are scheduled for liver biopsy for clinical reasons and their histopathology report confirms a diagnosis of NAFLD. NW control, and Ob control, and Liver control participants must not have diagnosed NAFLD.\n\nExclusion Criteria:\n\n* Chronic illness: Participants will not be able to participate if they have conditions that are likely to affect metabolic variables (either directly or due to required medications) or result in them being unable to complete the required tests. Such conditions could include, but are not limited to, untreated hypothyroidism or other endocrine disorders, rheumatoid arthritis requiring steroids or limiting mobility, cardiovascular disease, stroke, or cardiac failure, neurological disorders such as multiple sclerosis, cancer, liver diseases other than NAFLD (e.g., Wilson's disease), other organ disorders, or orthopedic conditions that limit physical activity.\n* Acute illness: Participants will not be able to participate if they develop acute conditions that are likely to affect metabolic outcomes (either directly or due to required medications) or result in them being unable to participate; e.g., respiratory illness, infectious disease, fever, accident resulting in bone fractures, myocardial infarction, major depression. If such conditions resolve and there are no longer risks or likelihood of adverse effect on the study outcomes, participants may be rescheduled for testing.\n* Medications and nutritional supplements: Medications, vitamins, or supplements that have known effects on the primary outcomes will be cause for exclusion. Examples include weight loss medications, glucocorticoids, or experimental medications used to correct a metabolic or hepatic condition. Medications used to control asthma, allergies, anxiety, depression, attention deficit disorder, menstrual cycle, hypothyroidism, gastric reflux, hypertension, and sleep will be allowed. Participants who are taking medications for treatment of acute illness or conditions such as cold, flu, injury, or infection will be rescheduled after they complete their treatment course.\n* Pregnancy: Evidence of pregnancy or intent to become pregnant during the study is cause for exclusion.\n* Smoking, alcohol abuse, or illicit drug abuse: Participants who smoke or have signs or symptoms of alcohol or substance abuse will be excluded.","10 Years","20 Years",{"count":152,"type":22},100,[69],"Nonalcoholic fatty liver disease (NAFLD) is now the most common liver disease worldwide and affects nearly 40% of obese youth and up to 10% of the general pediatric population. Some features of NAFLD are similar in children and adults, yet fibrosis and inflammation are more common in the portal zone and occur earlier in pediatric NAFLD patients than adults. This portends a rapid progression to end-stage liver disease in early adulthood. For the majority of children with NAFLD, mechanisms driving the origin and rapid progression of disease remain unknown. Thus, there is a critical, unmet need to study the specific underlying patterns of metabolic and molecular changes in the liver underlying the development and progression unique to children with NAFLD.\n\nThis proposal will test the hypotheses that children with NAFLD have excess glucose and lipid produced by the liver, that those events are regulated by specific variations in the amount and location of RNAs and proteins in liver, and that the concentration of specific micro-RNAs in the blood can be used as a biomarker for NAFLD in pediatric patients.",[29,126,99],"2024-03-04",{"date":158,"type":49},"2024-03-06",{"date":160,"type":49},"2022-05-25",{"date":162,"type":22},"2026-06",{"name":164,"class":56},"University of Oklahoma",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":92,"minAge":172,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":175,"phases":4,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":4},"100307440","great-china-fatter-liver-consortium-gcflc-study-to-assess-the-progress-of-nafldnash-in-chinese-100307440","NCT03282305","Great China Fatter Liver Consortium (GC_FLC) Study to Assess the Progress of NAFLD\u002FNASH in Chinese","Prospective Cohort Assessing the Prevalence and Progress of Non-alcoholic Fatty Liver Disease (NAFLD)\u002FNon-alcoholic Steatohepatitis (NASH) in Chinese","Inclusion Criteria:\n\n* Adults and children subjects aged \\>= 6 years old\n* Ability to understand and sign a written informed consent form (ICF) or provide assent in pediatric subjects\n* Diagnosis of NAFLD; or a definite or probable diagnosis of NASH:\n\n  1. A diagnosis of NAFLD will be defined by evidence of hepatic steatosis, either by imaging or by histology, with no causes for secondary hepatic fat accumulation such as significant alcohol consumption, use of steato-genic medication (e.g. valproate, amiodarone, anti-retroviral medications, tetracycline, chronic high-dose corticosteroids), or hereditary disorders (e.g. Wilson's disease, Wolman disease, cholesteryl-ester storage disease);\n  2. A definite diagnosis of NASH will be defined by steatohepatitis confirmed by biopsy with correlating clinical evidence of non-alcoholic liver disease;\n  3. A probable diagnosis of NASH will be defined by:\n\n     a.Elevated alanine amino transferase levels (ALT) of \\>40 U\u002FL; and b.Evidence of hepatic steatosis on imaging; or c.Obesity, type 2 diabetes, or pre-diabetes. Pre-diabetes is defined by: i.Impaired fasting glucose: 100 mg\u002FdL-125 mg\u002FdL (5.6 mmol\u002FL-6.9 mmol\u002FL) or; ii.Impaired glucose tolerance: 2-hr plasma glucose (PG) in 75-g Oral Glucose Tolerance Test (OGTT) 140 mg\u002FdL-199 mg\u002FdL (7.8 mmol\u002FL-11.0 mmol\u002FL) or; iii.HbA1C: 5.7%-6.4%.\n\n     Exclusion Criteria:\n* Unable to provide written informed consent (or assent in pediatric subjects)\n* Alcohol consumption greater than 21 units\u002Fweek for males or 14 units\u002Fweek for females (one unit of alcohol is half pint of beer \\[285 mL; 9.64 oz\\], 1 glass of spirits \\[25 mL; 0.85 oz\\] or 1 glass of wine \\[125 mL; 4.23 oz\\]\n* Enrolled in NASH-related clinical trials\n* Presence of other forms of chronic liver disease:\n\n  1. Chronic hepatitis B (HBsAg positive)\n  2. Chronic hepatitis C (HCV RNA positive)\n  3. Iron overload disorders (3-4+ iron on liver biopsy or known hemochromatosis gene (HFE) C282Y homozygous with ferritin \\> 200 ng\u002Fml; note: an elevated ferritin alone is common in NASH and is not exclusionary)\n  4. Autoimmune liver disease (biopsy evidence or clinical diagnosis of autoimmune hepatitis or Primary biliary cholangitis (PBC) requiring ongoing treatment, imaging evidence of Primary sclerosing cholangitis (PSC))\n  5. Wilson's disease\n  6. Alpha-1 antitrypsin mutations that in the opinion of the principal investigator is contributing to the patient's liver disease;\n* Prior bariatric surgery unless the surgery was performed more than one year before the biopsy diagnosis of NASH (i.e., NASH is present despite prior bariatric surgery);\n* Planned bariatric surgery (e.g. gastroplasty, roux-en-Y gastric bypass).","6 Years",{"count":174,"type":22},5000,"OBSERVATIONAL","Nonalcoholic fatty liver disease (NAFLD) is a progressive liver disease ranging from simple steatosis to cirrhosis of the liver. Nonalcoholic fatty liver (NAFL) without substantial hepatocellular injury is thought to be relatively benign whereas nonalcoholic steatohepatitis (NASH) is characterized by hepatocyte steatosis, ballooning, inflammation and varying degrees of fibrosis from none to cirrhosis. NASH is strongly associated with insulin resistance and metabolic syndrome and thus is recognized as a major public health concern as the most prevalent liver disease.\n\nLiver biopsy is the gold standard for a diagnosis of NASH. However, given the large population of patients at risk for NASH, liver biopsy is not a practical method for determining which patients may benefit from NASH therapy. Non-invasive methods to estimate inflammation and fibrosis are in clinical use, but there remains a dichotomy between gold standard inclusion criteria and end points that are utilized in clinical trials and real world diagnostic methods that are more common in clinical practice.\n\nThus, the investigators would like to conduct an observational study to head-to-head compare the non-invasive methods and liver biopsy in differential liver steatosis and liver biopsy in a real-world setting. Also, by following up patients for a relatively long time (proposed 10 years), the investigators can present the natural history of disease progression.",[29,126],"2018-02-04",{"date":180,"type":49},"2018-02-06",{"date":182,"type":22},"2018-04",{"date":184,"type":22},"2029-12",{"name":186,"class":187},"Great China Fatty Liver Consortium Limited","INDUSTRY"]